• Share
  • Email
  • Print

Virginia Tam

Fax +852.2511.9515
Ms. Tam focuses on outbound acquisitions and private equity investments for corporate and financial institution clients in Greater China. A lawyer experienced in U.S. securities laws and Hong Kong Listing Rules, Ms. Tam has worked on a broad range of matters within this practice area, including private and public acquisitions, private investment in publicly-traded equities (PIPEs), pre-IPO investments, joint ventures, capital market exits and privatizations.

Professional Background

Prior to joining K&L Gates, Ms. Tam was a partner in the Hong Kong office of another American law firm.

Presentations and Publications
Ms. Tam has spoken and published regularly on mergers and acquisitions, private equity and PIPEs at seminars and conferences in Greater China, including the Hong Kong chapter of Corporate Acquisitions and Mergers, a multi-volume, cross-border multi-jurisdictional guide published by Wolters Kluwer.

Mergers and Acquisitions
Strategic acquisitions
  • Advising the Hailiang Group, a PRC based conglomerate and the largest cooper wire manufacturer in the world, in the hostile takeover of Asa Resources Group plc, a UK listed company with mining operations in Africa, through a tender offer.
  • Advising TCL Corporation, a PRC listed telecommunications equipment manufacturer, in a proposed acquisition of the MiFi business of Novatel Wireless, Inc., a US listed company, through an asset sale.
  • Advising a Hong Kong listed PRC manufacturer in an all cash acquisition of a U.S. medical products company through multilateral stakeholder negotiations.
  • Advising Up Energy Development Group, a Hong Kong listed PRC coal mining company, in the distressed acquisition of Grande Cache Coal, a Canadian coal producer, from Winsway Enterprises Holdings, a Hong Kong listed company, and Marubeni Corporation, a Japan listed company, and the provision of US$73 million in interim financing to Grande Cache Coal.
  • Advising China Dongxiang (Group), a Hong Kong listed PRC sportswear brand enterprise, in the all cash acquisition of Point Roberts Resort Marina in Washington, the United States.
  • Advising a PRC listed pharmaceutical company in a proposed acquisition of a U.S. pharmaceutical manufacturer through a reverse triangular merger.
  • Advising a consortium of Taiwan-based minority shareholders in the privatization of Actions Semiconductor, a Nasdaq listed PRC integrated platform solutions provider.
  • Advising a third-party private equity consortium led by Leadyond Advisors, a PRC asset management company, in a leveraged management buyout of Wonder Auto Group, a PRC automobile parts manufacturer, following its Nasdaq delisting and SEC deregistration and the subsequent group restructuring.
  • Advising the special committee of the board of directors of 21Vianet Group, a Nasdaq listed PRC internet data center services provider, in a proposed privatization of 21Vianet Group by a consortium led by its controlling shareholder and strategic investors Kingsoft and Tsinghua Unigroup International.
  • Advising the special committee of the board of directors of Exceed Company, a Nasdaq listed PRC sportswear manufacturer and distributor, in a proposed privatization by a consortium led by its controlling shareholder.
Joint ventures and strategic alliances
  • Advising a PRC engineering products manufacturer in a private equity investment and the establishment of a PRC joint venture with a European medical device manufacturer.
  • Advising a PRC technology company in the establishment of a PRC joint venture with a Japanese conglomerate.
  • Advising TCL Corporation in a preferred stock and convertible notes investment in Palm Ventures Group, Inc., a mobile device developer and manufacturer, and its affiliate TCL Mobile International Limited in a manufacturing, licensing and distribution arrangements with Palm Ventures.
  • Advising Chinanx Financial Group, a PRC financial institution, as project fund manager in a strategic investment in NordAq, a U.S. oil and gas developer.
  • Advising a Guangzhou-based PRC pharmaceuticals manufacturer in a preferred stock investment in a biopharmaceuticals joint venture of a Nasdaq-listed company and its research and development, licensing and manufacturing arrangements in China.
  • Advising a Shenzhen-based PRC project fund in a strategic investment in the Greater China business of a U.S. optical products manufacturer.
Private Equity Transactions
Acquisition financings
  • Advising Shenzhen Blue Ocean Development Fund Management Company, as general partner, and its affiliated funds in its provision of mezzanine financing to Golden Meditech Holdings, a Hong Kong listed healthcare company, for the privatization of China Cord Blood Corporation, an NYSE listed PRC cord blood banking business, and the related exit transactions.
  • Advising China Development Bank International Investment Limited as private equity investor in the spin-off of the China business of Global Logistic Properties, a Singapore listed warehouse operator.
  • Advising China Regenerative Medicine International, a Hong Kong listed biopharmaceutical company, as anchor investor in a sector fund in the fund’s acquisition of Obagi Medical from the Canada listed Valeant Pharmaceuticals International.
  • Advising Haitong Securities International Limited in its provision of structured financing to Ping An ZQ China Growth Opportunity Limited in its strategic investment in an NYSE listed consumer beauty products company Nu Skin Enterprises.
  • Advising Shenzhen Blue Ocean Development Fund Management Company, as general partner, and its affiliated funds in its proposed provision of mezzanine financing for the privatization of Concord Medical Services, an NYSE listed cancer treatment services provider in the PRC and Singapore.
PIPE and pre-IPO transactions
  • Advising Kaisa Group, a Hong Kong listed PRC property developer, in its acquisition of a controlling stake from the founder of Nam Tai Property, a NYSE listed PRC property developer, and subsequent market purchases through purchases of ordinary shares.
  • Advising a consortium led by Luminary Capital, the family office of a Hong Kong veteran banker, in purchases of convertible notes and warrants from China Biomedicine Group, a Nasdaq listed PRC cellular therapy solutions developer, and the related exit transactions.
  • Advising Famous Sino Limited, a consortium led by industry veterans, in a purchase of convertible notes and warrants from Sorrento Therapeutics, a Nasdaq listed biomedical company.
  • Advising Perfect World Pictures, a PRC listed motions picture producer, in a pre-IPO subscription and purchase of shares in China Fortran Media Group, a PRC media marketing services provider, prior to its application for a Hong Kong listing and the related exit transactions.
Private equity and venture capital transactions
  • Represented G7 Networks, Inc. a PRC commercial telematics service provider, in its private equity financing through issuances of series D preferred stock with Hopu Fund as lead investor and its subsequent shareholding restructuring.
  • Advising Kai OS Technologies, a mobile software developer based in Hong Kong with operations in the United States and South America, in its seed financing from Reliance and venture capital financing from Google through issuances of common stock.
  • Advising NF Trinity Fund, the family office of Nam Fung Group, in their investment in a US biopharmaceuticals company through a subscription of common stock.
  • Advising Shenzhen Blue Ocean Development Fund Management Company in a venture capital investment in a U.S. biopharmaceuticals company through a purchase of preferred stock.